The USC Laboratory of Applied Pharmacokinetics and the International
Cancer Center, Rovigo, Italy, are pleased to announce a 1 Day workshop

Principles of Pharmacokinetics -
New Unified Approaches to Parametric and Nonparametric Population PK and PD Modeling - Applications to Therapeutic Drug Monitoring and to Optimal individualization of Drug Therapy and cancer chemotherapy.

Tuesday, December 3, 2002

Location -
International Cancer Center, Rovigo, Italy

This course is intended for physicians, pharmacists and biomedical scientists with an interest in population pharmacokinetic / pharmacodynamic modeling, and also for those interested in therapeutic drug monitoring and optimally precise individualization of drug therapy for patient care and cancer chemotherapy.

The course will examine and review current and new methods of parametric and nonparametric population PK/PD modeling, with special emphasis on the FOCE parametric Iterative 2 Stage Bayesian (IT2B) and the nonparametric adaptive grid (NPAG) programs.

This course will also introduce the new Win*USC*PACK software for "Multiple Model" design of dosage regimens that hit target goals with maximal precision. This method is based first on nonparametric population models. It also obtains a patient's Bayesian posterior nonparametric individual model, and, if needed, to detect and quantify the interoccasional variability in each patient's individual model, thus permitting detection of unsuspected changes in parameter values such as take place with the volume of distribution (and other parameters), in aminoglycoside antibiotics, for example, with changes in the patient's status. This sequential "Interacting Multiple Model" Bayesian approach to interoccasional intra-individual variability comes from the aerospace community, where it is used to track evasive targets. It is new, to our knowledge, in the pharmacokinetic community. It is designed to track the behavior of drugs, especially in unstable patients, with maximum precision, to detect unsuspected changes in a patient's parameter values during the period of the data analysis, and to permit achievement of target therapeutic goals with maximum precision. Such changes take place in patients not only when they are acutely ill and highly unstable, but also in children as they grow and mature, and therapy much be guided during all this time. In addition, changes also take place with varying compliance, and a changing apparent volume of distribution may well be a clue to good or poor compliance in a patient.

For more information and Registration, please contact

Prof. Maria Grazia Masucci
ICC Scientific Director
Rovigo, Italy


ICC Organizing Secretariat
Dr. Emanuela Pizzardo
Phone: +39 0425 394649
Fax: +39 0425 394624
e-mail: icconvegni@azisanrovigo.it

Further information is also available on our USC web site www.lapk.org

Faculty

Roger W. Jelliffe, M.D., Professor of Medicine, USC, Course coordinator.

Preliminary Program

Morning session Basic Pharmacokinetics, Introduction to Population Modeling 

8:30 AM - Welcome : Prof. Maria Grazia Masucci
8:45 AM	- Review of Basic Pharmacokinetic Behavior.
	  Drug Elimination and Renal Function - Dr. Jelliffe
9:00 AM - Evaluating Renal Function  and Creatinine clearance in unstable patients
9:15 AM - Bayes' Theorem and the Bayesian Scenario of Planning, Monitoring, and 
          Adjusting Drug Dosage for patients 
9:30 AM - Introduction to Population Modeling -
	  Determining the assay error polynomial - 
	  Parametric Models -  Iterative 2 stage Bayesian 
	  Nonparametric models - NPEM, NPML, NPAG

10:00 AM BREAK

10:15 AM - When to get serum samples
10:45 AM - Therapeutic outcomes to date: Digoxin, Lidocaine, Aminoglycosides, 
	   Vancomycin, Busulfan, Cyclosporine, and comments on Methotrexate
11:15 AM - Multiple Model Dosage Design - MM-USC*PACK
11:45 AM - Application to Gentamicin, Tobramycin, Vancomycin
12:30 PM - Digoxin. The Reuning population model.
	   Setting goals in the peripheral compartment
	   Two interesting patients with atrial fiibrillation.
	   The digoxin - quinidine interaction - implications for transplant and 
	   cancer chemotherapy.

13:00 PM - Adjourn